Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

Arena Pharma claims new lysophospholipid S1P1 receptor agonists

Feb. 3, 2011

CHMP recommends approval of BF-200 ALA for actinic keratosis

Feb. 1, 2011

New lysophospholipid S1P1 receptor agonists patented

Feb. 1, 2011

Galderma claims novel inhibitors of ADAM 17

Jan. 28, 2011

ChemoCentryx begins phase I trial of CCX-832 under alliance with GSK

Jan. 27, 2011

Galderma discloses novel inhibitors of ADAM 17

Jan. 26, 2011

Dutch scientists present new bradykinin B1 receptor antagonists

Jan. 26, 2011

R-Tech Ueno completes phase IIa RK-023 trial in androgenetic alopecia

Jan. 25, 2011

Ono Pharmaceutical divulges new chymase inhibitors

Jan. 20, 2011

Abbott withdraws European MAA for Ozespa

Jan. 19, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...